Global CAR-T Therapy Pipeline Analysis Market Report 2023: Increasing Financial Support Provided by Different Organizations to Promote Development and Consumption Drives Growth

Rhea-AI Summary

The CAR-T Therapy Pipeline Analysis Global Market Report 2023 has been released by ResearchAndMarkets.com, detailing significant growth in the CAR-T therapy market. The market is projected to expand from $1.40 billion in 2021 to $1.80 billion in 2022, reflecting a CAGR of 28.6%. By 2026, the market is expected to reach $3.55 billion, growing at a CAGR of 18.5%. Major players include Legend Biotech, Novartis AG, and Kite Pharma. The report highlights the role of financial support for CAR-T therapy development and notes the impact of high costs and limitations in treating certain cancers as challenges. The leading regions are North America and Western Europe, while the main product types include monotherapy and combination therapy targeting cancers such as acute lymphoblastic leukemia.

Positive

• Projected market growth from $1.40 billion in 2021 to $3.55 billion by 2026.
• Strong CAGR of 28.6% from 2021 to 2022.
• Increasing financial support for CAR-T therapy development.

Negative

• High treatment costs exceeding $1 million per patient.
• Limitations in treating various cancers restrict market growth.
• Potential side effects such as cytokine release syndrome.

DUBLIN, April 6, 2023 /PRNewswire/ -- The "CAR-T Therapy Pipeline Analysis Global Market Report 2023" report has been added to  ResearchAndMarkets.com's offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the market.

The global car-t therapy pipeline analysis market is expected to grow from $1.40 billion in 2021 to $1.80 billion in 2022 at a compound annual growth rate (CAGR) of 28.6% The chimeric antigen receptor -T therapy market is expected to grow to $3.55 billion in 2026 at a CAGR of 18.5%. 

Major players in the chimeric antigen receptor -T therapy market are Novartis AG, Kite Pharma, Pfizer Inc, Juno Therapeutics, Celgene Corporation, CARsgen Therapeutics, Sorrento Therapeutics, Legend Biotech, Mustang Bio, and Immune Therapeutics.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis

The chimeric antigen receptor -T therapy market includes revenues earned by CAR-T therapy products and related services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The chimeric antigen receptor -T therapy is a type of immunotherapy in which T-cells are taken from the patient's blood are modified in a laboratory with the addition of a special protein receptor that grants T-cells the power to recognize as well as kill cancer cells easily, along with infusing the same back into that patient. This special protein receptor, known as the chimeric antigen receptor (CAR), attaches to a specific protein on a patient's cancer cells. The infused cells multiply and prevail in the patient's body as living drugs.

North America was the largest region in the global CAR-t therapy market in 2022. Western Europe was the second-largest region in the CAR-T therapy market. The regions covered in chimeric antigen receptor -T therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The main types of chimeric antigen receptor -T therapy is monotherapy and combination therapy. Monotherapy is used in the treatment of any disease with a single drug. The target antigens involved are CD19, CD22, and others that are used in various applications such as acute lymphoblastic leukemia, diffuse large b-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma, and others.

The CAR-T therapy market is driven by the increasing financial support provided by different organizations to promote the development and consumption of CAR-T therapy. The government and non-government organizations provide financial support to the companies in the CAR-T therapy market for research and development and the patients for their treatment of acute lymphoblastic leukemia (ALL).

The limitations on the application of CAR-T therapy limit the growth of the market. The limitations of CAR-T therapy include its failure to treat other types of cancer, side effects, and the high cost of treatment. CAR-T therapy is widely used as a treatment for a particular type of blood cancer and fails to treat other types of cancers such as lung cancer or breast cancer.

Further, in many cases, the application of CAR-T therapy results in cytokine release syndrome (CRS). CRS is a severe flu-like condition causing high fever, nausea, chills, headache, rash, and troubled breathing. Further, the high cost limits the growth of the market. According to a report from Kaiser Health News, the per-patient cost of CAR-T cell therapy was more than $1 million in 2021. Thus, the growth of CAR-T therapy is restricted by the various limitations on the application of CAR-T therapy.

The companies in the CAR-T therapy market are conducting clinical trials to assess the ability of CAR-T therapy to treat multiple myeloma. Multiple myeloma is a type of white blood cell cancer where the cancer cells accumulate in the bone marrow and surrounds the healthy blood cells. CAR-T therapy is being tested as a treatment for multiple myeloma. CAR-T cells are modified to target the multiple myeloma causing cells to treat the relapsed or refractory multiple myeloma (RRMM).

The countries covered in the chimeric antigen receptor -T therapy market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.

Key Topics Covered:

1. Executive Summary

2. CAR-T Therapy Market Characteristics

3. CAR-T Therapy Market Trends And Strategies

4. CAR-T Therapy Market- Macro Economic Scenario
4.1 COVID-19 Impact On CAR-T Therapy Market
4.2 Ukraine-Russia War Impact On CAR-T Therapy Market
4.3 Impact Of High Inflation On CAR-T Therapy Market

5. CAR-T Therapy Market Size And Growth
5.1. Global CAR-T Therapy Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global CAR-T Therapy Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. CAR-T Therapy Market Segmentation
6.1. Global CAR-T Therapy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Monotherapy
• Combination Therapy

6.2. Global CAR-T Therapy Market, Segmentation By Target Antigen, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• CD19
• CD22
• Other Target Antigen

6.3. Global CAR-T Therapy Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Acute Lymphoblastic Leukemia
• Diffuse Large B-Cell Lymphoma
• Follicular Lymphoma
• Chronic Lymphocytic Leukemia
• Multiple Myeloma
• Other Applications

7. CAR-T Therapy Market Regional And Country Analysis
7.1. Global CAR-T Therapy Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global CAR-T Therapy Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

For more information about this report visit https://www.researchandmarkets.com/r/86vcvr

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/global-car-t-therapy-pipeline-analysis-market-report-2023-increasing-financial-support-provided-by-different-organizations-to-promote-development-and-consumption-drives-growth-301791809.html

SOURCE Research and Markets

FAQ

What is the projected growth of the CAR-T therapy market?

The CAR-T therapy market is expected to grow from $1.40 billion in 2021 to $3.55 billion by 2026.

What are the major players in the CAR-T therapy market?

Key players include Legend Biotech, Novartis AG, Kite Pharma, and Pfizer.

What challenges does the CAR-T therapy market face?

The market faces challenges such as high treatment costs and limitations in treating a wider range of cancers.

What was the market size for CAR-T therapy in 2022?

The market size for CAR-T therapy was $1.80 billion in 2022.

What types of therapy are included in the CAR-T therapy market?

The CAR-T therapy market includes monotherapy and combination therapy targeting various cancers.